Research across Diabetes
Related studies from across the Diabetes family.
15 trials tracked for Diabetic Nephropathy: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 133 citations.
Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Canagliflozin has demonstrated significant clinical benefits in patients with diabetic nephropathy. It significantly reduced the primary composite endpoint of doubling of serum creatinine, end-stage kidney disease, and renal or cardiovascular death (61.24% vs 43.21%, p<0.0001) 7. Additionally, Canagliflozin was associated with a significant reduction in the composite endpoint of cardiovascular death and hospitalized heart failure (45.44% vs 31.47%, p=0.0001) and a reduction in major adverse cardiac events (MACE) (48.67% vs 38.71%, p=0.0121) 7.
While Canagliflozin showed significant reductions in composite renal and cardiovascular outcomes, specific findings regarding eGFR decline were mixed; one trial reported no statistically significant difference in the change from baseline in eGFR at week 104 (p=0.351) 6. In other trials, standard of care was associated with a reduction in MACE compared to alternative treatments (146 vs 116, p<0.05) 1.
Other interventions investigated include sodium bicarbonate 2, Cyclosporin 3, Lipo-PGE1 4, Sulodexide 5, and Losartan 8. Olmesartan medoxomil showed no significant difference in renal composite outcomes (p=0.79) but did show a statistically significant reduction in cardiovascular composite outcomes (40 vs 53, p=0.039) 9.
AI synthesis of 12 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Diabetes family.